Daniel L. Kisner - 13 Jun 2023 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 13 Jun 2023
Net transaction value: -$40.03
SEC form: 4
Accepted by SEC: 15 Jun 2023, 16:29:40 UTC
Prior SEC filing: 31 May 2023
Next SEC filing: 21 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Albert P. Parker, Attorney-in-Fact

Key filing fact

Daniel L. Kisner filed Form 4 for Zynerba Pharmaceuticals, Inc. on 15 Jun 2023.

Key facts

This page summarizes Daniel L. Kisner's Form 4 filing for Zynerba Pharmaceuticals, Inc..
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2023, 16:29.

Change

Previous filing in this sequence was filed on 31 May 2023.
Current net transaction value: -$40.03.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZYNE transaction

Common Stock

Award

Transaction value: $0
Shares: +47,824
Change %: +170%
Price: $0.000000
Shares after: 75,893
Date: 13 Jun 2023
Ownership: Direct
Footnotes: F1

ZYNE transaction

Common Stock

Sale

Transaction value: $40.03
Shares: -115
Change %: -0.15%
Price: $0.3481
Shares after: 75,778
Date: 14 Jun 2023
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZYNE transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +71,736
Change %
Price: $0.000000
Shares after: 71,736
Date: 13 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 71,736
Exercise price: $0.3501
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The restricted stock award vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders.

Footnote F2

This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees and taxes in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.

Footnote F3

The option vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders.